- Home
- ADSE vs CDNA Comparison
ADSE vs CDNA Comparison
Compare ADSE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- CDNA
- Stock Information
- Founded
- ADSE 1980
- CDNA 1998
- Country
- ADSE Ireland
- CDNA United States
- Employees
- ADSE N/A
- CDNA N/A
- Industry
- ADSE Industrial Specialties
- CDNA Medical Specialities
- Sector
- ADSE Consumer Discretionary
- CDNA Health Care
- Exchange
- ADSE Nasdaq
- CDNA Nasdaq
- Market Cap
- ADSE 777.7M
- CDNA 844.7M
- IPO Year
- ADSE N/A
- CDNA 2014
- Fundamental
- Price
- ADSE $11.14
- CDNA $17.08
- Analyst Decision
- ADSE
- CDNA Buy
- Analyst Count
- ADSE 0
- CDNA 6
- Target Price
- ADSE N/A
- CDNA $30.33
- AVG Volume (30 Days)
- ADSE 71.0K
- CDNA 1.4M
- Earning Date
- ADSE 05-12-2025
- CDNA 07-30-2025
- Dividend Yield
- ADSE N/A
- CDNA N/A
- EPS Growth
- ADSE N/A
- CDNA N/A
- EPS
- ADSE N/A
- CDNA 1.07
- Revenue
- ADSE $113,896,884.00
- CDNA $346,421,000.00
- Revenue This Year
- ADSE $219.58
- CDNA $13.38
- Revenue Next Year
- ADSE N/A
- CDNA $15.33
- P/E Ratio
- ADSE N/A
- CDNA $16.00
- Revenue Growth
- ADSE 2.45
- CDNA 25.92
- 52 Week Low
- ADSE $10.17
- CDNA $13.07
- 52 Week High
- ADSE $16.35
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- ADSE 45.53
- CDNA 50.50
- Support Level
- ADSE $11.07
- CDNA $16.22
- Resistance Level
- ADSE $13.36
- CDNA $18.02
- Average True Range (ATR)
- ADSE 1.04
- CDNA 0.77
- MACD
- ADSE 0.05
- CDNA 0.12
- Stochastic Oscillator
- ADSE 57.66
- CDNA 59.83
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services which enable the customer to control and manage the system. Geographically, it derives a majority of its revenue from Europe.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.